/ /

  • linkedin
  • Increase Font
  • Sharebar

    The case of the disappearing drusen

    Anti-VEGF therapy leads to significant improvement in drusen

    At her periodic eye examination, a female patient in her early 70s was discovered to have low-risk macular degeneration in each eye. Further evaluation revealed that her visual acuity (VA) was correctable to 20/25 in each eye. Her medical history was remarkable for systemic hypertension treatment she received for at least 10 years. 

    The patient was neurologically intact, had intraocular pressures (IOP) in the statistically normal range, anterior segments were unremarkable for her age, and she had age-appropriate lens changes. Except for the refractive correction (low-degree hyperopic astigmatism, presbyopia) and fundus findings, the remaining ocular history and findings were noncontributory. At baseline, the drusen presentation was minimal, and the patient was asked to self-monitor for vision changes and return in one year (Figure 1).

    Follow-up and treatment

    One year later, at the follow-up examination, the right eye showed some minimal advancement of drusen in the macula. However, he left eye had developed wet age-related macular degeneration (AMD), and VA had deteriorated to 20/200 (Figure 2). The patient claimed to be unaware of the visual deficit. 

    The patient was sent for consultation with a retina specialist who administered an anti-VEGF agent in each eye based on a fluorescein angiography (FA) study. 

    As expected, the clinical picture in the left eye was not altered, nor was VA. Strikingly, at our follow-up visit which took place two years from the baseline fundus photograph of the right eye, the drusen landscape showed significant improvement (Figure 3). 

    On follow-up over the next four years, the clinical picture in the right eye had deteriorated to the point of requiring repeated anti-VEGF injections. The VA in the left eye has remained stable (20/200), but the VA of the right eye had slowly declined to 20/60 despite repeated anti-VEGF treatments.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V